A study of danazol's safety.

Jick SS, S S Jick, Susan S. Jick, Michael W. Myers, M W Myers, Myers MW
Pharmacotherapy · 1996 · vol. 15(6) , pp. 740–1 · PMID:8602381 · W1589869025
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-07 ⓘ

A review of 530 danazol recipients found 29% reported adverse events within 45 days, though none required hospitalization or caused long-term sequelae.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a review of medical records of 530 recipients of danazol at Group Health Cooperative of Puget Sound, we identified 154 (29%) people who reported at least one adverse event that occurred within 45 days after receiving the drug. In no patient did the event require hospitalization, and there were no known long-term sequelae.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Estrogen Antagonists Adult Danazol Drug Eruptions Drug Eruptions Endometriosis Endometriosis Estrogen Antagonists Female Fibrocystic Breast Disease Fibrocystic Breast Disease Humans Male Retrospective Studies

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
openalex
last seen: 2026-05-11T04:23:31.979020+00:00
pubmed
last seen: 2026-05-13T22:11:08.331550+00:00
License: CC0 · commercial use OK